Measles surveillance rises while vaccine-safety reporting changes advance

An increasing disease burden

CDC’s total includes 18 international visitors and compares with 2,289 cases in all of 2025. It lists two deaths, subject to additional review, and is working toward standardized mortality reporting.

The MMR guidance

CDC continues to recommend two routine childhood doses of measles, mumps and rubella (MMR) vaccine. Its approximately 97% two-dose effectiveness estimate is established guidance rather than a newly measured 2026 outbreak result.

Seasonal recommendations

CDC’s September 23 COVID-19 guidance distinguishes adults, children and immune status and identifies off-label uses. Readers need the current age- and product-specific schedule rather than one rule inferred from a general announcement.

Care and reporting actions

HHS says a National Institutes of Health clinic opened October 5. Physician payment for submitting suspected injuries remains proposed; electronic-record changes and modernization of the Vaccine Adverse Event Reporting System (VAERS) are separate implementation projects.

How safety evidence should be read

VAERS accepts suspected events without requiring proof of causation. Reports can be incomplete or duplicated across submissions. FDA’s RSV warning is an example of a product-specific observational signal that still carries explicit causal uncertainty.

The next checks

Follow reconciled mortality definitions, verified schedule changes, implemented reporting standards and carefully adjudicated safety studies. A higher reporting count alone cannot establish a higher injury rate.

What to watch next

CDC/state mortality reconciliation, formal clinical guidance, reporting-rule implementation and product-specific active surveillance.

Material unknowns

• CDC's two-dose MMR schedule remains operational; its historical estimate is 97% protection against measles after two doses, not a 2026 outbreak-specific effectiveness study. The federal and Pennsylvania mortality counts cannot simply be added, because case overlap is unknown. CDC says death classifications may change. Vaccination-status categories combine unknown with unvaccinated in the rapid dashboard. A VAERS submission is a safety signal, not proof of causation; no new active-surveillance finding superseded the standing confirmed injury rates. COVID XFG clinical effectiveness remains unavailable at this cutoff.